The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1377
November 14, 2011
View Complete Issue         Table of Contents 2019 
Tadalafil (Cialis) for Signs and Symptoms of Benign Prostatic Hyperplasia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tadalafil (Cialis) for Signs and Symptoms of Benign Prostatic Hyperplasia
November 14, 2011 (Issue: 1377)
The FDA has approved the use of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil (Cialis – Lilly) for treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in men with or without erectile dysfunction. Tadalafil is approved for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tadalafil (Cialis) for Signs and Symptoms of Benign Prostatic Hyperplasia
Article code: 1377b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.